Interpace Biosciences, Inc. 8-K Filing
Ticker: IDXG · Form: 8-K · Filed: Dec 3, 2025 · CIK: 1054102
| Field | Detail |
|---|---|
| Company | Interpace Biosciences, Inc. (IDXG) |
| Form Type | 8-K |
| Filed Date | Dec 3, 2025 |
| Pages | 1 |
| Reading Time | 2 min |
| Sentiment | neutral |
Sentiment: neutral
FAQ
What type of filing is this?
This is a 8-K filing submitted by Interpace Biosciences, Inc. (ticker: IDXG) to the SEC on Dec 3, 2025.
How long is this filing?
Interpace Biosciences, Inc.'s 8-K filing is 1 pages with approximately 431 words. Estimated reading time is 2 minutes.
Where can I view the full 8-K filing?
The complete filing is available on SEC EDGAR. You can also read the AI-decoded analysis with risk assessment and key highlights on ReadTheFiling.
Filing Stats: 431 words · 2 min read · ~1 pages · Grade level 10.6 · Accepted 2025-12-03 16:05:28
Filing Documents
- form8-k.htm (8-K) — 36KB
- ex99-1.htm (EX-99.1) — 13KB
- 0001493152-25-025960.txt ( ) — 211KB
- idxg-20251203.xsd (EX-101.SCH) — 3KB
- idxg-20251203_lab.xml (EX-101.LAB) — 33KB
- idxg-20251203_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 3KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. INTERPACE BIOSCIENCES, INC. By: /s/ Thomas W. Burnell Name: Thomas W. Burnell Title: President and Chief Executive Officer Date: December 3, 2025